Onsdag 28 Oktober | 19:00:26 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Episurf Medical - Q1’22 Review

2022-05-02 10:00:00

Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and notes several crucial activities carried out that should ignite a more significant sales growth beyond 2022.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/